Infectious Disease Doctors in Gainesville, FL Accepting Medicare

25 Infectious Disease doctors found. Showing 21 - 25

Shannon N. Moonah, M.D. Internal Medicine - Infectious Disease Medicare: Medicare Enrolled Practice Location: 1601 S.w. Archer Road, Gainesville, FL 32608 Phone: 352-548-6000

Dr. Frederick S Southwick, MD Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1600 Sw Archer Rd, Gainesville, FL 32610 Phone: 352-392-4058

Dr. Luis Alejandro Perez-mena, MD Internal Medicine - Infectious Disease Medicare: Medicare Enrolled Practice Location: 7003 Nw 11th Pl Ste 6, Gainesville, FL 32605 Phone: 352-554-5000    Fax: 352-554-4626

Nayrobi Maitelic Pena Cotui, MD Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1600 Sw Archer Rd, Gainesville, FL 32610 Phone: 352-273-9804    Fax: 352-392-6481

Dr. Asmita A. Gupte, MD Internal Medicine - Infectious Disease Medicare: Medicare Enrolled Practice Location: 1600 Sw Archer Rd, Gainesville, FL 32610 Phone: 352-392-4058    Fax: 352-392-6481

News Archive

Efficacy of Ugandan HIV prevention programs decreasing

The efficacy of Uganda's HIV prevention programs is decreasing because a new generation of young people are no longer receiving the messages of fidelity that helped curb the country's HIV epidemic in the late 1980s and early 1990s, the Washington Post reports.

Electromed first quarter net revenues increase 29% to $4,165,000

Electromed, Inc. today announced financial results for the three months ended September 30, 2010. Net revenues for the three months ended September 30, 2010 were approximately $4,165,000, a 29% increase compared to net revenues of approximately $3,228,000 for the same period last year.

Alexion acquires Enobia Pharma

Alexion Pharmaceuticals, Inc. today announced that the Company has completed its previously announced acquisition of 100% of the capital stock of Enobia Pharma Corp., a private biopharmaceutical company focused on the development of therapies to treat patients with ultra-rare and life-threatening genetic metabolic disorders.

Keryx Biopharmaceuticals commences Phase 3 registration program for Zerenex

Keryx Biopharmaceuticals, Inc. announced today the initiation of its short-term Phase 3 study of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.

Read more Medical News

› Verified 6 days ago

• 1
• 2(current)